Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis To Expand China’s Flu Vaccine Market

This article was originally published in PharmAsia News

Executive Summary

Once its Shenzhen flu vaccine production plant goes into operation in 2012, Sanofi-Aventis plans to sell 15 million doses of seasonal flu vaccine annually in China. A company official reveals that the estimate is based on projected global need of 1.3 billion vaccine doses by 2016, with China being one of the major markets. However, the country's inoculation rate stands at a mere 1.5 percent compared with 20 to 40 percent in Europe and North America. Moreover, over 60 percent of China's users opt for low-cost domestic products. Sanofi thus needs to decrease its production cost. Analysts note that without a consortium to standardize vaccine production and management locally, replicated and wasted efforts are hampering promotion and widespread usage. (Click here for more - Chinese Language)

You may also be interested in...

Sanofi Pasteur To Produce Influenza A (H1N1) Vaccine In Shenzhen By 2012

Sanofi Pasteur is intensifying efforts to build a vaccine production base in Shenzhen (PharmAsia News, Oct. 20, 2008). The first phase of construction on the facility was completed in October 2008, and the entire project is scheduled to be completed by 2012. The facility will produce mainly influenza vaccines for influenza A and B type H1N1 and H3N2, with an annual output for 25 million people. To facilitate the project, Shenzhen municipal government will handle all issues of certification and licenses as well as business consulting by the end of December. (Click here for more - Chinese Language)

QUOTED. 24 November 2020. Kees Wesdorp.

Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.

Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue

Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts